Lead Product(s) : S-531011
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 01, 2021
Lead Product(s) : S-531011
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
First-in-human Study of S-588210 (S-488210+S-488211)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 20, 2020
Lead Product(s) : Ospemifene
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : QuatRx Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
April 26, 2012
Lead Product(s) : Ospemifene
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : QuatRx Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ospemifene
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : QuatRx Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
April 26, 2012
Lead Product(s) : Ospemifene
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : QuatRx Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable